Previous 10 | Next 10 |
Viatris Announces Approval of Emissions Reduction Targets by the Science Based Target initiative (SBTi) PR Newswire PITTSBURGH , Dec. 14, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that its near-term sci...
Summary Humira's international sales were $603 million in Q3 2022, down 25.7% year-over-year, and this is mainly due to increased competition from biosimilars in Europe. AbbVie's EBITDA was $7,235 million in Q3 2022, up 2.8% year-on-year. The largest contribution to the company's re...
Summary We've witnessed such a quick and sharp correction in the stock market that the S&P 500 nearly moved from bear-market to bull-market in a matter of weeks. Nonetheless, there are still plenty of signs suggesting that this rapid move isn't going to last much longer, therefore w...
Investors looking to boost their income often turn to high-yielding dividend stocks. If they invest in quality stocks, they can generate recurring revenue. If they invest in quality stocks that are currently trading at depressed valuations related to the bear market, they can also benefit from th...
FARMINGTON HILLS, Mich., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced the submission of a...
Viatris Completes Biosimilars Transaction with Biocon Biologics PR Newswire Receives a $2 Billion Cash Payment and $1 Billion of Convertible Preferred Equity Representing a Stake of at Least 12.9% (on a Fully Diluted Basis) in Biocon Biologics ...
AbbVie (NYSE: ABBV) and Viatris (NASDAQ: VTRS) have a lot more in common than first glances would suggest. The two were both spun off from larger companies and now deliver above-average dividend yields. As pharmaceutical companies, they provide the potential for stea...
Viatris Named U.S. In-House Legal Team of the Year for Intellectual Property Litigation by LMG Life Sciences PR Newswire PITTSBURGH , Nov. 18, 2022 /PRNewswire/ -- Viatris Inc . (NASDAQ: VTRS), a global healthcare company, today announced that it...
Fresenius Medical Care (NYSE: FMS) , Pfizer (NYSE: PFE) , and Viatris (NASDAQ: VTRS) have seen their shares slide so far this year. That may be bad news for their current investors, but it could be good news for the companies' future investors. I believe these ...
Summary Davis Selected Advisers 13F portfolio value decreased from $15.59B to $14.06B this quarter. They increased Meta Platforms and Teck Resources while reducing Intel, Loews, and Alibaba Group Holding. The top three positions are Wells Fargo, Berkshire Hathaway, and Capital...
News, Short Squeeze, Breakout and More Instantly...
2024-07-26 12:25:00 ET The late comedian Rodney Dangerfield was famous for his catchphrase, "I don't get no respect." Does Dangerfield's line apply to some stocks today? Absolutely. Three Motley Fool contributors think they've found surprisingly underrated pharmaceutical stocks to b...
NORTHAMPTON, MA / ACCESSWIRE / July 23, 2024 / No country can make every medicine people need, and no medicine is made in every country. If a country or region relies on supply only from within their region and they experience a crisis, there is a risk people won't get the medicines they need, w...
NORTHAMPTON, MA / ACCESSWIRE / July 18, 2024 / Viatris is a global healthcare company focused on bringing high-quality medicines to patients through a hybrid approach that bridges the traditional divide between generics and brands, combining the best of both, to more holistically address healthc...